Methamphetamine damages monoamine-containing nerve terminals in the brains of both animals and human drug abusers, and the cellular mechanisms underlying this injury have been extensively studied. More recently, the growing evidence for methamphetamine influences on memory and executive function of human users has prompted studies of cognitive impairments in methamphetamine-exposed animals. After summarizing current knowledge about the cellular mechanisms of methamphetamine-induced brain injury, this review emphasizes research into the brain changes that underlie the cognitive deficits that accompany repeated methamphetamine exposure. Novel approaches to mitigating or reversing methamphetamine-induced brain and behavioral changes are described, and it is argued that the slow spontaneous reversibility of the injury produced by this drug may offer opportunities for novel treatment development.
Introduction
Methamphetamine (mAMPH) is a highly addictive, widely abused psychostimulant drug. First synthesized in 1893 [1] , mAMPH has been used for the treatment of attention deficit hyperactivity disorder, narcolepsy, asthma, and obesity [2] [3] [4] [5] . Owing to its ease of synthesis from commonly available precursors, mAMPH abuse in the US has reached near-epidemic proportions. Acutely, mAMPH intake leads to euphoria, increased vigilance, hyperactivity, and cardiovascular changes -actions that are similar to those of other psychostimulant drugs [6] . However, when taken repeatedly or in higher doses, mAMPH can result in adverse physiological and neurological consequences including weight loss, muscular wasting, periodontal necrosis, brain injury, and impaired attention, memory and executive functions. After a single dose, amphetamines persist in the human body for nearly a day [7] , and this long duration of action is thought to contribute to the brain injury and cognitive impairments seen in mAMPH abusers. Recently, much new information has been acquired about how mAMPH affects the brain and behavior of both human users and animals. This review will emphasize the evidence germane to three questions: (i) what are the brain changes seen in the mAMPH-using population, and do these changes represent enduring brain injury? (ii) What can animal models reveal about the effects of mAMPH exposure on persisting neural and behavioral impairments? (iii) Is brain injury needed for mAMPH-induced cognitive impairments to occur?
mAMPH-induced brain changes in animal models
When discussing the action of a drug it is important to distinguish acute versus persistent effects. Similarly to other amphetamines, mAMPH interacts with nerve terminals that use catecholamines (dopamine, DA and norepinephrine, NE) or the indoleamine, serotonin (5-HT), as neurotransmitters. Whether swallowed, snorted, smoked, or taken intravenously, mAMPH crosses the blood-brain barrier (BBB) and enters these terminals, inducing a nonexocytotic transmitter 'release'. At least two general actions of mAMPH contribute to this monoamine transmitter release: (i) redistribution of amines from synaptic vesicle sites into the cytoplasm, and (ii) reverse transport of the monoamine transmitters from the cytoplasm to the extracellular space via their plasma-membrane uptake carriers [8] . These acute drug actions, especially those occurring in the DA nerve terminals of the striatum (caudate nucleus, putamen, and nucleus accumbens (NAc) area of humans), account for the initial euphoric and other stimulatory actions of mAMPH [9] .
In addition to these acute actions, mAMPH is capable of inducing long-lasting brain changes. Such long-term effects include: (i) the development of compulsive patterns of mAMPH use, (ii) induction of brain injury, and (iii) alterations in the cognitive functions of the mAMPH-using population. Research using animals (most often, rodents) and employing several different mAMPH dosing regimens (Box 1) has been essential to characterize mechanisms underlying these enduring effects of mAMPH. These animal models include: (i) mAMPH self-administration to study drug-seeking, (ii) escalating mAMPH dose regimens to examine the enhanced neurobehavioral influences of mAMPH with repeated exposure, (iii) mAMPH conditioned place preference (CPP) to investigate the neural substrates of the rewarding effects of this drug, and (iv) binge mAMPH administration models that readily induce neurotoxicity of brain DA and 5-HT systems. Animal research has played an especially important role in these investigations because only in animals can the exposure to mAMPH be isolated from the other variables (pharmacologic, genetic, environmental) that affect brain and cognition.
Psychostimulant-induced neurotoxicity has most commonly been modeled in rodents by administering
